# A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161

> **NCT02125162** · PHASE1 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** BCX4161

## Key facts

- **NCT ID:** NCT02125162
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125162, "A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02125162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*